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Manuscript 
Although AST-to-platelet ratio index (APRI) and FIB-4 have been compared with liver 
biopsy in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), HIV/HCV co-
infection, and HIV/HBV co-infection, Johannessen and Lemoine stress that they have 
not been validated in HIV mono-infected populations in SSA. However, this is unlikely to 
occur because liver biopsy does not play a role in HIV management and the procedure 
carries its own risks for complication. Clinicians using APRI and FIB-4 in this setting 
should be aware of this limitation and should interpret test results in the context of each 
patient’s clinical scenario. 
 
While it elevates APRI or FIB-4 scores, HIV-associated thrombocytopenia (HAT) does 
not fully explain the association of these markers with mortality. In our analysis, an 
elevated APRI score at start of antiretroviral therapy predicted all-cause mortality — 
even among patients with WHO clinical stage 1 or 2 and CD4+ counts >200 cells/mm2 
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who were unlikely to have HAT [1]. In a sensitivity analysis not included in the primary 
manuscript, we replaced each patient’s platelet count with the median value of 238 x 
109/L. As expected, the percentage with APRI ≥1.5 decreased from 5.1% to 1.9%; 
however, the association with mortality was similar (adjusted hazard ratio 1.62; 95% CI, 
1.29-2.05). 
 
In their letter to the editor, Johannessen and Lemoine speculate that the excess 
mortality experienced by patients with elevated APRI was unlikely a direct result of liver 
disease. Unfortunately, as is common in Africa, causes of death were not available in 
our large observational cohort, making this a difficult question to answer. However liver-
related mortality was plausible, since HIV itself can interact with and infect multiple liver 
cell types [2,3] with potential clinical consequences [4] that are not fully understood, and 
chronic HBV, the leading cause of advanced liver disease in Africa, was not 
comprehensively screened for in our cohort. Further investigation is needed to better 
understand the contribution of liver disease to all-cause mortality among patients on HIV 
treatment.  
 
Finally, it is important to note that APRI and FIB-4 independently predicted ART 
mortality in our analysis and may thus have a prognostic role in HIV care in SSA. As our 
colleagues suggest, further research is certainly needed to better define underlying 
biological mechanisms to determine how to incorporate their use at scale. Given the 
limited capacity for diagnosis and management of liver disease, however, such non-
invasive metrics appear highly promising for future work. 
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